The Journal publishes important advances in DNA, RNA, cell and immune therapies, validating the latest advances in research and new technologies.Established in 1990, HGT provides a prestigious forum for publishing scientific and clinical research, including ethical, legal, regulatory, social, and commercial issues, which enables the advancement and progress of therapeutic procedures leading to improved patient outcomes, and ultimately, to curing diseases. European Editor: Hildegard Büning, PhD Gene and Cell Therapy Connect - a free, comprehensive news source delivered bimonthly to readers. journal self-citations removed) received by a journal's published documents during the three previous years. Human Gene Therapy and HGT Methods provide “Instant Online” publication 72 hours after acceptance. The Official Journal of nine international societies: The first peer-reviewed journal in the field of human gene therapy, providing all-inclusive coverage of the research, methods, and clinical developments that are driving today's explosion of gene therapy advances. Human Gene Therapy was the first journal devoted to cover the field of gene therapy. The Journal publishes important advances in DNA, RNA, cell and immune therapies, validating the latest advances in research and new technologies. The SJR is a size-independent prestige indicator that ranks journals by their 'average prestige per article'. The set of journals have been ranked according to their SJR and divided into four equal groups, four quartiles. ISSN: 1043-0342. Impact Factor: * 4.510 *2019 Journal Citation Reports (Clarivate, 2020) The first peer-reviewed journal in the field of human gene therapy, providing all-inclusive coverage of the research, methods, and clinical developments that are driving today's explosion of gene therapy advances. Ratio of a journal's items, grouped in three years windows, that have been cited at least once vs. those not cited during the following year. Human gene therapy: scientific and ethical considerations. Human Gene Therapy Impact Factor, IF, number of article, detailed information and journal factor. Data Source: Scopus®, Metrics based on Scopus® data as of April 2020, Biochemistry, Genetics and Molecular Biology. The chart shows the evolution of the average number of times documents published in a journal in the past two, three and four years have been cited in the current year. The chart shows the ratio of a journal's documents signed by researchers from more than one country; that is including more than one country address. The Journal publishes important advances in DNA, RNA, cell and immune therapies, validating the latest advances in research and new technologies. Human Gene Therapy Methods Impact Factor, IF, number of article, detailed information and … This indicator counts the number of citations received by documents from a journal and divides them by the total number of documents published in that journal. Basic and clinical advances in gene therapy, Small nucleic acid therapeutics, including RNAi, Clinical trials (including confirmatory or negative results), Pre-clinical animal/in vitro studies to assess safety of gene and cell therapy products, Commercial development of gene and cell therapy products. Human Gene Therapy (HGT) is the premier, multidisciplinary journal covering all aspects of gene therapy. Compared with historical Journal Impact data, the Metric 2019 of Human Gene Therapy dropped by 15.63% . Audience: Geneticists, medical geneticists, molecular biologists, virologists, experimental researchers, and experimental medicine specialists, among others. Follow us on @ScimagoJRScimago Lab, Copyright 2007-2020. It is based on the idea that 'all citations are not created equal'. Human Gene Therapy is under the editorial leadership of Editor-in-Chief Terence R. Flotte, MD, University of Massachusetts Medical School and other leading investigators. SJR is a measure of scientific influence of journals that accounts for both the number of citations received by a journal and the importance or prestige of the journals where such citations come from Somatic cell gene therapy is technically the simplest and ethically the least controversial. Editor-in-Chief: Terence R. Flotte, MD Anderson WF. Clinical development dropped by 3.61% . The Journal Impact 2019-2020 of Human Gene Therapy is 3.670, which is just updated in 2020. The Journal Impact 2019-2020 of Human gene therapy. Impact of Gene Therapy Gene therapy has many benefits to humans but there are also some negative aspects of gene therapy. The journal also publishes a wide range of reviews, commentaries and editorials. The views, opinions, findings, conclusions and recommendations set forth in any Journal article are solely those of the authors of those articles and do not necessarily reflect the views, policy or position of the Journal, its Publisher, its editorial staff or any affiliated Societies and should not be attributed to any of them. Impact Factor: *4.510 *2019 Journal Citation Reports (Clarivate, 2020) CiteScore™: 6.8. Journal Self-citation is defined as the number of citation from a journal citing article to articles published by the same journal. International Collaboration accounts for the articles that have been produced by researchers from several countries. Human Gene Therapy (HGT) is the premier, multidisciplinary journal covering all aspects of gene therapy. *2019 Journal Citation Reports (Clarivate, 2020), “All in One” 24/7 home cage monitoring: Improving model translation, animal welfare and data reproducibility, Roundtable Discussion on Leaps in Innovation in Cancer Immunology, Home-Cage Monitoring and its Effects on Research Capability and Outcomes, Onco Cell Therapy Summit (OCTS) (Digital Event), American Society of Gene & Cell Therapy (ASGCT) Annual Meeting. Clinical development is 2.400, which is just updated in 2020. Human Gene Therapy (HGT) is the premier, multidisciplinary journal covering all aspects of gene therapy. Established in 1990, HGT provides a prestigious forum for publishing scientific and clinical research, including ethical, legal, regulatory, social, and commercial issues, which enables the advancement and progress of therapeutic procedures leading to improved patient outcomes, and ultimately, to curing diseases. Not every article in a journal is considered primary research and therefore "citable", this chart shows the ratio of a journal's articles including substantial research (research articles, conference papers and reviews) in three year windows vs. those documents other than research articles, reviews and conference papers. The users of Scimago Journal & Country Rank have the possibility to dialogue through comments linked to a specific journal. The Journal Impact Quartile of Human Gene Therapy is Q1 . The first peer-reviewed journal in the field of human gene therapy, providing all-inclusive coverage of the research, methods, and clinical developments that are driving today's explosion of gene therapy advances. Deputy Editor-in-Chief: Guangping Gao, PhD External citations are calculated by subtracting the number of self-citations from the total number of citations received by the journal’s documents. The purpose is to have a forum in which general doubts about the processes of publication in the journal, experiences and other issues derived from the publication of papers are resolved. HGT is published 12 times per year, including sections on Methods (product testing and development) and Clinical Development (regulatory review, toxicology and commercial development). The term 'gene therapy' encompasses at least four types of application of genetic engineering for the insertion of genes into humans. Q1 (green) comprises the quarter of the journals with the highest values, Q2 (yellow) the second highest values, Q3 (orange) the third highest values and Q4 (red) the lowest values. Deputy Editors: Mark Kay, MD, PhD, Thierry VandenDriessche, PhD, and Cheng Seng, PhD, New eBook: “All in One” 24/7 home cage monitoring: Improving model translation, animal welfare and data reproducibility, Free Download: Roundtable Discussion on Leaps in Innovation in Cancer Immunology.